Arix Bioscience has announced that Dr Christian Schetter has joined its investment team as entrepreneur in residence (EIR), and will be based in Munich, but will also spend a lot of time in the London office.
With over 20 years’ industry experience across the life sciences sector, Dr Christian joins Arix from German immuno-oncology company Rigontec GmbH, where he was CEO for four years. He was also part of the leadership team which built Coley Pharmaceuticals from inception, and following several significant pharma deals, saw it through to a trade sale to Pfizer in 2007.
After receiving an undergraduate degree and PhD from the University of Cologne, he went on to do postdoctoral research in oncology and virology at the Scripps Research Institute in La Jolla, California.
Joe Anderson, Chief Investment Officer of Arix said: “I am delighted to welcome Christian to the team. He has a track record of creating companies that foster exciting science and securing impressive exits. His extensive experience of building companies in the life science industry will greatly benefit Arix as we continue to build on our existing investments and leverage our extensive pipeline.”
